Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A 'Human immunodeficiency virus-infected cell' is any human cell that has been infected by the human immunodeficiency virus (HIV). The most common host cells are CD4+ T lymphocytes, macrophages, and dendritic cells. This term does not refer to a single defined molecule or canonical therapeutic target, but to a physiopathological state. Drug development for HIV infection usually focuses on viral proteins (e.g., reverse transcriptase, integrase, protease, envelope glycoproteins gp120/gp41) or host cell receptors required for HIV entry (e.g., CD4, CCR5, CXCR4). These molecules—rather than the infected cell as a category—are recognized as valid drug targets[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus-infected cell.